Differential effects of amphetamine and neuroleptics on negative Vs. positive symptoms in schizophrenia
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Positive symptoms of schizophrenia were diminished by neuroleptics and increased by amphetamine and accounted for most of the change seen in the total Brief Psychiatric Rating Scale (BPRS). Negative symptoms in the same subjects were not affected by neuroleptics but increased after amphetamines to a degree that just attained statistical significance. This increase was due to one item (emotional withdrawal) of the negative symptom factor which responded to neuroleptics and amphetamines as did positive symptoms. These findings are discussed with respect to new ideas about the role of dopamine in schizophrenia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Administration of stimulants to unmedicated schizophrenic patients can enhance positive symptoms (Angrist et al 1980, van Kammen et al 1982), which is likely due to subcortical D2 receptor activation.”
From Prefrontal cortex executive processes affected by stress in health and disease (2018) · cites this paper as Angrist et al 1980, van Kammen et al 1982
Citations
Cites
Research Diagnostic Criteria: Rationale and Reliability
Spitzer, R. L. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770300115013 · Cited by 6,951
Molecular pathology of schizophrenia: more than one disease process?
Crow, T. J. (1980) · BMJ · doi:10.1136/bmj.280.6207.66 · Cited by 1,856
CEREBRAL VENTRICULAR SIZE AND COGNITIVE IMPAIRMENT IN CHRONIC SCHIZOPHRENIA
Johnstone, E., Frith, C. D., Crow, T. J., Husband, J., & Kreel, L. (1976) · The Lancet · doi:10.1016/s0140-6736(76)90890-4 · Cited by 1,253
The Dopamine Hypothesis of Schizophrenia: A Review*
Meltzer, H. Y., & Stahl, S. M. (1976) · Schizophrenia Bulletin · doi:10.1093/schbul/2.1.19 · Cited by 883
Kono, R., Miyamura, K., OGINO, T., Wadia, N. H., Wadia, P. N., Sm, K., & Vp, M. (1981) · PubMed · Cited by 578
MECHANISM OF THE ANTIPSYCHOTIC EFFECT IN THE TREATMENT OF ACUTE SCHIZOPHRENIA
Johnstone, E., Frith, C. D., Crow, T. J., Carney, M. W. P., & Price, J. S. (1978) · The Lancet · doi:10.1016/s0140-6736(78)90193-9 · Cited by 458
Hormones, Behavior, and Psychopathology
SACHAR, E. J. (1977) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-197709000-00013 · Cited by 330
Weinberger, D. R. (1980) · Archives of General Psychiatry · doi:10.1001/archpsyc.1980.01780140013001 · Cited by 323
The dementia of dementia praecox
Johnstone, E. C., Crow, T. J., Frith, C. D., Stevens, M., Kreel, L., & Husband, J. (1978) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1978.tb06899.x · Cited by 270
Responses to apomorphine, amphetamine, and neuroleptics in schizophrenic subjects
Angrist, B., Rotrosen, J., & Gershon, S. (1980) · Psychopharmacology · doi:10.1007/bf00427592 · Cited by 140
Self-citation
Research works printed but not linked: 1
- Guy W (1976) E.C.D.E.U. assessment manual for psychopathology. Washington D.C.: U.S. Department of Health, Education and Welfare, pp 160, 162, 167
Cited by
Items 101–200 of 371
Stevens, J. R., & Gold, J. M. (1991) · Behavioral and Brain Sciences · doi:10.1017/s0140525x00065377 · Cited by 82
Negative and depressive symptoms in suicidal schizophrenics
Jones, J. S., Stein, D. J., Stanley, B., Guido, J. R., Winchel, R., & Stanley, M. (1994) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1994.tb01491.x · Cited by 80
Significance of the Positive-negative Distinction in Schizophrenia
Kay, S. R. (1990) · Schizophrenia Bulletin · doi:10.1093/schbul/16.4.635 · Cited by 79
Disrupted Pattern of D2 Dopamine Receptors in the Temporal Lobe in Schizophrenia: A Postmortem Study
Goldsmith, S. K. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830190077008 · Cited by 71
Orienting Response Research in Schizophrenia: Where We Have Come and Where We Might Go
Bernstein, A. S. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.4.623 · Cited by 77
Lee, T., & Tang, S. W. (1984) · Psychiatry Research · doi:10.1016/0165-1781(84)90044-1 · Cited by 76
Möller, H. ‐. (1993) · European Neuropsychopharmacology · doi:10.1016/0924-977x(93)90289-x · Cited by 76
Fanous, A. H., Neale, M. C., Straub, R. E., Webb, B. T., O’Neill, F. A., Walsh, D., & Kendler, K. S. (2003) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.20103 · Cited by 72
Sources of Diagnostic Uncertainty for Chronically Psychotic Cocaine Abusers
Shaner, A. L., Roberts, L. J., Eckman, T. A., Racenstein, J. M., Tucker, D. E., TSUANG, J. W., & Mintz, J. (1998) · Psychiatric Services · doi:10.1176/ps.49.5.684 · Cited by 70
Docherty, N. M., Schnur, M., & Harvey, P. D. (1988) · Journal of Abnormal Psychology · doi:10.1037//0021-843x.97.4.437 · Cited by 69
Schiz bits: Misses, mysteries and hits
Gray, J. A., Hemsley, D. R., Feldon, J., Gray, N. S., & Rawlins, J. N. P. (1991) · Behavioral and Brain Sciences · doi:10.1017/s0140525x00065420 · Cited by 69
Dysphoric mood and symptomatology in schizophrenia
Norman, R. M. G., & Malla, A. K. (1991) · Psychological Medicine · doi:10.1017/s0033291700029883 · Cited by 56
Williams, J. H., Wellman, N. A., Geaney, D. P., Cowen, P. J., Feldon, J., & Rawlins, J. N. P. (1996) · Biological Psychiatry · doi:10.1016/s0006-3223(95)00629-x · Cited by 66
Schizophrenia and the D1 receptor: Focus on negative symptoms
Lynch, M. R. (1992) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(92)90102-k · Cited by 64
Positive and negative subtypes of schizophrenia
Kulhara, P., & Chandiramani, K. (1990) · Schizophrenia Research · doi:10.1016/0920-9964(90)90043-7 · Cited by 64
Oades, R. D., R�pcke, B., & Eggers, C. (1994) · Journal of Neural Transmission · doi:10.1007/bf01277936 · Cited by 64
Verbal hallucinations and information processing
Rund, B. R. (1986) · Behavioral and Brain Sciences · doi:10.1017/s0140525x00046975 · Cited by 64
Construct validity of negative symptoms: An empirical and conceptual review
Earnst, K. S., & Kring, A. M. (1997) · Clinical Psychology Review · doi:10.1016/s0272-7358(96)00052-9 · Cited by 63
Verheij, M. M. M., & Cools, A. R. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.02.084 · Cited by 61
Cooper, S. J., Butler, A., Tweed, J. A., Welch, C. P., & Raniwalla, J. (2000) · Psychopharmacology · doi:10.1007/s002130000452 · Cited by 61
Effect of subtle neurological dysfunction on response to haloperidol treatment in schizophrenia
Convit, A. J., Volavka, J., Czobor, P., de Asis, J. M., & Evangelista, C. (1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.1.49 · Cited by 61
Singh, M. M., Kay, S. R., & Opler, L. A. (1987) · Psychological Medicine · doi:10.1017/s0033291700012964 · Cited by 54
CEREBRAL VENTRICULAR SIZE: A BIOLOGICAL MARKER FOR SUB-TYPING CHRONIC SCHIZOPHRENIA
Weinberger, D. R., & Wyatt, R. J. (1982) · Elsevier eBooks · doi:10.1016/b978-0-08-027987-9.50054-8 · Cited by 57
Batki, S. L., & Harris, D. S. (2004) · American Journal on Addictions · doi:10.1080/10550490490512834 · Cited by 56
5-HT2C Agonists Modulate Schizophrenia-Like Behaviors in Mice
Pogorelov, V. M., Rodriguiz, R. M., Cheng, J., Huang, M., Schmerberg, C. M., Meltzer, H. Y., Roth, B. L., Kozikowski, A. P., & Wetsel, W. C. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.52 · Cited by 55
Amphetamine response and relapse risk after depot neuroleptic discontinuation
ANGRIST, B. M., Peselow, E. D., Rubinstein, M. E., Wolkin, A., & Rotrosen, J. (1985) · Psychopharmacology · doi:10.1007/bf00428187 · Cited by 55
Self-citationA cross-national factor analytic comparison of three models of PANSS symptoms in schizophrenia
Stefanovics, E. A., Elkis, H., Zhe-ning, L., Zhang, X. Y., & Rosenheck, R. A. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2014.04.041 · Cited by 54
Distinguishing depression and negative symptoms in unmedicated patients with schizophrenia
Newcomer, J. W., Faustman, W. O., Yeh, W., & Csernansky, J. G. (1990) · Psychiatry Research · doi:10.1016/0165-1781(90)90093-k · Cited by 54
Amphetamine and negative symptoms of schizophrenia
Sanfilipo, M. P., Wolkin, A., ANGRIST, B. M., Duncan, E., Wieland, S., Peselow, E. D., Rotrosen, J., van Kammen, D. P., & Cooper, T. B. (1996) · Psychopharmacology · doi:10.1007/bf02246180 · Cited by 52
Self-citationWadenberg, M.-L. G., Browning, J. L., Young, K. A., & Hicks, P. B. (2001) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(00)00483-4 · Cited by 52
Facial expression in schizophrenia
Earnst, K. S., Kring, A. M., Kadar, M. A., Salem, J. E., Shepard, D. A., & Loosen, P. T. (1996) · Biological Psychiatry · doi:10.1016/0006-3223(96)00171-0 · Cited by 51
Psychopathology and Individual Differences in Latent Inhibition: Schizophrenia and Schizotypality
Lubow, R. E., & Kaplan, O. (2010) · Plenum series on human exceptionality · doi:10.1007/978-1-4419-1210-7_11 · Cited by 51
Haloperidol plasma levels and clinical response in paranoid schizophrenics
Linkowski, P., Hubain, P., von Frenckell, R., & Mendlewicz, J. (1984) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/bf00381354 · Cited by 50
Ellenbroek, B. A., Lubbers, L. J., & Cools, A. R. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(96)00001-2 · Cited by 49
Stauffer, V. L., Song, G., Kinon, B. J., Ascher‐Svanum, H., Chen, L., Feldman, P. D., & Conley, R. R. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.09.028 · Cited by 48
(2001) · PubMed · Cited by 47
Schuldberg, D., Quinlan, D. M., Morgenstern, H., & Glazer, W. M. (1990) · Psychological Assessment · doi:10.1037/1040-3590.2.3.262 · Cited by 47
Frecska, E., Perényi, A., Bagdy, G., & Révai, K. (1985) · Psychiatry Research · doi:10.1016/0165-1781(85)90109-x · Cited by 47
Tandon, R., GOLDMAN, R. S., Goodson, J. A., & Greden, J. F. (1990) · Biological Psychiatry · doi:10.1016/0006-3223(90)90502-s · Cited by 47
The neurobiology of relapse in schizophrenia
Remington, G. J., Foussias, G., Agid, O., Fervaha, G., Takeuchi, H., & Hahn, M. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.10.009 · Cited by 46
Foss‐Feig, J. H., McPartland, J. C., Anticevic, A., & Wolf, J. M. (2015) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-015-2539-x · Cited by 45
The amphetamine challenge test in patients with borderline disorder
(1988) · American Journal of Psychiatry · doi:10.1176/ajp.145.7.809 · Cited by 34
Crow, T. J. (1982) · Cellular and Molecular Life Sciences · doi:10.1007/bf01954914 · Cited by 45
Behavioral and biochemical effects of methylphenidate in schizophrenic and nonschizophrenic patients
Sharma, R. P., Javaid, J. I., Pandey, G. N., Janicak, P. G., & Davis, J. M. (1991) · Biological Psychiatry · doi:10.1016/0006-3223(91)90307-8 · Cited by 44
Antipsychotic Agents: A Clinical Update
Black, J. L., Richelson, E., & Richardson, J. W. (1985) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)60421-2 · Cited by 44
Is negative schizophrenia a variant of parkinsonism?
Sandyk, R., & Kay, S. R. (1990) · International Journal of Neuroscience · doi:10.3109/00207459008986609 · Cited by 44
Tandon, R. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00103-7 · Cited by 38
A Developmental History of the Positive and Negative Syndrome Scale (PANSS).
Liechti, S., Capodilupo, G., Opler, D. J., Opler, M. G. A., & Yang, L. H. (2017) · PubMed · Cited by 37
Naber, D., Albus, M., Bürke, H., Müller-Spahn, F., Münch, U., Reinertshofer, T., Wissmann, J., & Ackenheil, M. (1985) · Psychiatry Research · doi:10.1016/0165-1781(85)90108-8 · Cited by 37
Negative Symptoms in Schizophrenia: A Target for New Drug Development
Meltzer, H. Y., & Zureick, J. L. (1989) · Springer eBooks · doi:10.1007/978-3-642-74430-3_8 · Cited by 37
The Glutamate Hypothesis of Schizophrenia: Therapeutic Implications
Ishimaru, M. J., & Toru, M. (1997) · CNS Drugs · doi:10.2165/00023210-199707010-00006 · Cited by 36
Szeszko, P. R., Bilder, R. M., Dunlop, J. A., Walder, D. J., & Lieberman, J. A. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00258-3 · Cited by 36
A Longitudinal Study of Thought Disorder in Manic Patients
Harrow, M., Grossman, L. S., Silverstein, M. L., Meltzer, H. Y., & Kettering, R. L. (1986) · Archives of General Psychiatry · doi:10.1001/archpsyc.1986.01800080067009 · Cited by 36
L-DOPA in the Treatment of Negative Schizophrenic Symptoms: A Single-Subject Experimental Study
Kay, S. R., & Opler, L. A. (1986) · The International Journal of Psychiatry in Medicine · doi:10.2190/lmel-l5hq-peqv-vycj · Cited by 36
SCHIZOPHRENIA, PSYCHOSIS, AND THE BASAL GANGLIA
Busatto, G. F., & Kerwin, R. W. (1997) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70351-8 · Cited by 36
Presynaptic Receptors on Catecholamine Neurones
Langer, S. Z., & Lehmann, J. C. (1988) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-46625-0_8 · Cited by 36
Cho, H. S., D’Souza, D. C., Gueorguieva, R. V., Perry, E. B., Madonick, S. H., Karper, L. P., Abi‐Dargham, A., Belger, A., Abi‐Saab, W., Lipschitz, D. S., et al. (2005) · Psychopharmacology · doi:10.1007/s00213-004-2066-5 · Cited by 35
Bishop, R. J., Golden, C. J., Maclnnes, W. D., Chu, C.-C., Ruedrich, S., & Wilson, J. (1983) · Psychiatry Research · doi:10.1016/0165-1781(83)90047-1 · Cited by 35
New pharmacotherapeutic modalities for negative symptoms in psychosis
Lindenmayer, J. (1995) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1995.tb05939.x · Cited by 35
Symptom provocation studies in psychiatric disorders: scientific value, risks, and future
D’Souza, D. C., Berman, R., Krystal, J. H., & Charney, D. S. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00209-7 · Cited by 32
Effect of Antipsychotic Withdrawal on Negative Symptoms in Schizophrenia
Miller, D. D., Flaum, M. A., Arndt, S. V., Fleming, F. W., & Andreasen, N. C. (1994) · Neuropsychopharmacology · doi:10.1038/npp.1994.31 · Cited by 32
Motor perseverations in schizophrenia
Bilder, R. M., & Goldberg, E. (1987) · Archives of Clinical Neuropsychology · doi:10.1016/0887-6177(87)90009-6 · Cited by 32
Patterns of schizophrenia symptoms: hidden structure in the PANSS questionnaire
Lefort‐Besnard, J., Varoquaux, G. P., Derntl, B., Gruber, O., Aleman, A., Jardri, R., Sommer, I. E., Thirion, B., & Bzdok, D. (2018) · Translational Psychiatry · doi:10.1038/s41398-018-0294-4 · Cited by 30
Amphetamines for schizophrenia
Nolte, S., Wong, D., Latchford, G. J., Boyle, O., & Anaenugwu, A. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004964 · Cited by 30
A realistic model will be much more complex and will consider longitudinal neuropsychodevelopment
Patterson, T. (1991) · Behavioral and Brain Sciences · doi:10.1017/s0140525x00065286 · Cited by 30
Rowley, H. L., Needham, P. L., Kilpatrick, I. C., & Heal, D. J. (2000) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s002109900170 · Cited by 29
5-HIAA in Cerebrospinal Fluid and Deficit Schizophrenic Characteristics
Csernansky, J. G., King, R., Faustman, W. O., Moses, J. A., Poscher, M. E., & Faull, K. F. (1990) · The British Journal of Psychiatry · doi:10.1192/bjp.156.4.501 · Cited by 29
Matsumoto, J., Nishimaru, H., Takamura, Y., Urakawa, S., Ono, T., & Nishijo, H. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00399 · Cited by 28
Clinical implications of determination of plasma haloperidol levels
Santos, J. L., Cabranes, J. A., Almoguera, I., Ramos, J. A., Vázquez, C., & Angeles, F. (1989) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1989.tb10269.x · Cited by 28
Developmental dysregulation of the dopamine system and the pathophysiology of schizophrenia
Grace, A. A. (2004) · Cambridge University Press eBooks · doi:10.1017/cbo9780511735103.017 · Cited by 28
The Relevance of the Dopamine-D1 Receptor in the Cognitive Symptoms of Schizophrenia
Goldman-Rakic, P. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00107-4 · Cited by 27
The Two-Syndrome Concept and Neuroendocrinology of Schizophrenia
Crow, T. J., Ferner, I. N., & Johnstone, E. C. (1986) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(18)30637-3 · Cited by 27
Association study of SNAP25 and schizophrenia in Irish family and case–control samples
Fanous, A. H., Zhao, Z., van den Oord, E. J. C. G., Maher, B. S., Thiselton, D. L., Bergen, S. E., Wormley, B., Bigdeli, T. B., AMDUR, R. L., O’Neill, F. A., et al. (2009) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.31037 · Cited by 26
The Assessment of Negative and Positive Features in Schizophrenia
Johnstone, E. C. (1989) · The British Journal of Psychiatry · doi:10.1192/s0007125000291460 · Cited by 26
Schizophrenia: Nature of the Disease Process and its Biological Correlates
Crow, T. J., & Johnstone, E. C. (1987) · Comprehensive physiology · doi:10.1002/cphy.cp010521 · Cited by 26
Schmidt‐Hansen, M., & Pelley, M. E. L. (2012) · Cognitive Neuropsychiatry · doi:10.1080/13546805.2012.667202 · Cited by 25
The Relationship of Negative Schizophrenia to Parkinsonism
Sandyk, R., & Kay, S. R. (1990) · International Journal of Neuroscience · doi:10.3109/00207459008987178 · Cited by 25
An open trial of adjunctive sertraline in the treatment of chronic schizophrenia
Thakore, J. H., Berti, C., & Dinan, T. G. (1996) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1996.tb09848.x · Cited by 24
Possible Noradrenergic Dysfunction in Schizophrenia
Yamamoto, K., Ozawa, N., Shinba, T., Hoshino, T., & Yoshii, M. (1994) · Brain Research Bulletin · doi:10.1016/0361-9230(94)90167-8 · Cited by 24
Psychopharmacologic Management of Traumatic Brain Injury
Cardenas, D. D., & McLean, A. (1992) · Physical Medicine and Rehabilitation Clinics of North America · doi:10.1016/s1047-9651(18)30646-6 · Cited by 24
Psychopharmacologic treatment of negative schizophrenic symptoms
Opler, L. A., Albert, D. B., & RAMIREZ, P. M. (1994) · Comprehensive Psychiatry · doi:10.1016/0010-440x(94)90165-1 · Cited by 24
Language process and hallucination phenomenology
Alpert, M. (1986) · Behavioral and Brain Sciences · doi:10.1017/s0140525x00046811 · Cited by 24
Auditory hallucinations, inner speech, and the dominant hemisphere
Flor-Henry, P. (1986) · Behavioral and Brain Sciences · doi:10.1017/s0140525x00046860 · Cited by 23
Symptômes Positifs Et Négatifs De La Schizophrénie: Une Mise à jour
Roy, M., & Devriendt, X. (1994) · The Canadian Journal of Psychiatry · doi:10.1177/070674379403900704 · Cited by 23
Clinical response and plasma haloperidol levels in chronic and subchronic schizophrenia
Santos, J. L., Cabranes, J. A., Vázquez, C., Fuentenebro, F., Almoguera, I., & Ramos, J. A. (1989) · Biological Psychiatry · doi:10.1016/0006-3223(89)90054-1 · Cited by 23
Amphetamine Challenge Test, response to treatment, and lateral ventricle size in schizophrenia
Pandurangi, A. K., Goldberg, S. C., Brink, D. D., Hill, M. H., Gulati, A. N., & Hamer, R. M. (1989) · Biological Psychiatry · doi:10.1016/0006-3223(89)90165-0 · Cited by 23
Akins, K. A., & Dennett, D. C. (1986) · Behavioral and Brain Sciences · doi:10.1017/s0140525x00046793 · Cited by 22
Depressive symptoms and schizophrenic relapses: The effect of four neuroleptic drugs
Mauri, M. C., Bitetto, A., Fabiano, L. R. F. L. R., Laini, V., Steinhilber, C. P. C., Fornier, M. N., & Rafique, F. (1999) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(98)00090-6 · Cited by 22
Brain ventricular size and CSF monoamine metabolites in an adolescent inpatient population
Jennings, W. S., Schulz, S. C., Narasimhachari, N., Hamer, R. M., & Friedel, R. O. (1985) · Psychiatry Research · doi:10.1016/0165-1781(85)90001-0 · Cited by 22
Numan, N. A. (2012) · Cited by 21
Angrist, B., Sanfilipo, M. P., & Wolkin, A. (2001) · Clinical Neuropharmacology · doi:10.1097/00002826-200105000-00004 · Cited by 21
Self-citationIs it possible to model psychotic states in animals?
Iversen, S. D. (1987) · Journal of Psychopharmacology · doi:10.1177/026988118700100303 · Cited by 21
Pigache, R. M. (1993) · Schizophrenia Research · doi:10.1016/0920-9964(93)90075-t · Cited by 21
Negative Symptoms in Schizophrenia: Relationship to Positive Symptoms and Outcome
Lieberman, J. A., Jody, D. N., Alvir, J. M., Borenstein, M., Mayerhoff, D. I., Geisler, S., Szymanski, S., Gonzales, A. H., Bogerts, B., & Ashtari, M. (1991) · Springer eBooks · doi:10.1007/978-3-642-76841-5_8 · Cited by 20
Predicting haloperidol treatment response in chronic schizophrenia
van Kammen, D. P., Kelley, M. E., Yao, J. K., Gilbertson, M. W., Gurklis, J. A., Inosaka, T., Saito, H., Peters, J. L., & Sato, M. (1996) · Psychiatry Research · doi:10.1016/0165-1781(96)02906-x · Cited by 20
Boyer, P., & Puech, A. J. (1987) · Psychiatry and Psychobiology · doi:10.1017/s0767399x0000095x · Cited by 20
Akhondzadeh, S., Mojtahedzadeh, V., Gh.R., M., Moin, M., Amini‐Nooshabadi, H., & Kamalipour, A. (2002) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.2002.00445.x · Cited by 19
Distinctiveness, unintendedness, location, and nonself attribution of verbal hallucinations
Junginger, J. (1986) · Behavioral and Brain Sciences · doi:10.1017/s0140525x00046926 · Cited by 18
Cantrup, R., Sathanantham, K., Rushlow, W. J., & Rajakumar, N. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.07.027 · Cited by 18
Suzuki, E., Kanba, S., Nibuya, M., Adachi, S., Sekiya, U., Shintani, F., Kinoshita, N., Yagi, G., & Asai, M. (1994) · Biological Psychiatry · doi:10.1016/0006-3223(94)91174-6 · Cited by 18
Metadata
- Authors
- Angrist, B., Rotrosen, J., & Gershon, S.
- Affiliations
- United States Department of Veterans Affairs (US)
- Wayne State University (US)
- ORCID
- Rotrosen, J.
- Venue
- Psychopharmacology
- Published
- 1980-12
- Volume
- 72
- Issue
- 1
- Pages
- 17-19
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W2050121560
- Cited by
- 344
- References
- 11
- Citations by year
- 2026: 1 · 2021: 3 · 2020: 1 · 2019: 2 · 2018: 1 · 2017: 3 · 2016: 4 · 2015: 5 · 2014: 2 · 2013: 4 · 2012: 8
- FWCI
- 6.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
- Keywords
- amphetamine, antipsychotic drugs, schizophrenia, negative symptoms, positive symptoms, Brief Psychiatric Rating Scale, emotional withdrawal, dopamine, psychopharmacological effects
- MeSH terms
- Adult, Affect, Dextroamphetamine, Dopamine, Female, Haloperidol, Humans, Male, Psychiatric Status Rating Scales, Schizophrenia, Schizophrenic Psychology, Antipsychotic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.